Evidence map›Paper›PMID 40866517›Full record

ArticleScientific reports2025

Single-cell transcriptomic analysis of blood and bronchoalveolar lavage fluid in progressive fibrosing interstitial lung diseases.

Aki Sakashita, Aiko Hirano, Wataru Fujii, Kevin Baßler, Taisuke Tsuji, Masatoshi Kadoya, Atsushi Omoto, Noriya Hiraoka, Tatsuya Imabayashi, Yoshiko Kaneko and 9 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Aki Sakashita *Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.ORCID http://orcid.org/0000-0002-1633-8255
Aiko Hirano *Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Wataru FujiiInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan. snufkin@koto.kpu-m.ac.jp.
Kevin Baßleraimed analytics GmbH, Bonn, Germany.
Taisuke TsujiDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Masatoshi KadoyaCenter for Rheumatic Disease, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Atsushi OmotoCenter for Rheumatic Disease, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Noriya HiraokaDepartment of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Tatsuya ImabayashiDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yoshiko KanekoDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hideaki SofueInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Yosuke MaeharaDepartment of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Takahiro SenoInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Makoto WadaInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Masataka KohnoInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Wataru FukudaCenter for Rheumatic Disease, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Kei YamadaDepartment of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Koichi TakayamaDepartment of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yutaka KawahitoInflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465, Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.

Funding

GlaxoSmithKline Japan A-87Ministry of Education, Culture, Sports, Science and Technology of Japan JP19K24000
6 · The paper itself

Abstract

This study investigates the pathophysiology of progressive fibrosing interstitial lung disease (PF-ILD) and identifies biomarkers that predict PF-ILD in patients with ILD by analyzing immune cells in both the blood and bronchoalveolar lavage fluid (BALF). This prospective cohort study involved 43 newly diagnosed ILD patients with various connective tissue diseases, from whom BALF and blood samples were collected for analysis. Using Seq-Well, a portable platform for single-cell RNA sequencing, we assessed gene expression in immune cells from both BALF and blood. Additionally, levels of cytokines, chemokines, and complements in the BALF supernatant and plasma were measured using an enzyme-linked immunosorbent assay. In total, 12 patients fulfilled the diagnostic criteria for PF-ILD and exhibited an increase in mononuclear myeloid cells expressing chemokines, such as CCL10 and CCL4, along with plasma cells in their BALF. Additionally, elevated levels of cytokines, including IL-6, CXCL10, and arginase, as well as increased complement activation, were observed in the BALF of patients with PF-ILD. Our findings suggest that active inflammation by macrophages and plasma cells along with complement activation in the lungs may be associated with the progression of pulmonary fibrosis. BALF analysis is beneficial for assessing immune responses and predicting progressive fibrosis in the lungs.

Indexed as

Bronchoalveolar Lavage FluidLung Diseases, InterstitialPulmonary FibrosisSingle-Cell AnalysisTranscriptomeAgedBiomarkersChemokinesCytokinesDisease ProgressionFemaleGene Expression ProfilingHumansMaleMiddle AgedProspective StudiesBiomarkersChemokinesCytokinesBronchoalveolar lavage fluidConnective tissue diseaseInterstitial lung diseaseProgressive fibrosing interstitial lung diseaseProgressive pulmonary fibrosisSingle-cell RNA sequencing

Identifiers

PMID40866517
PMCPMC12391471

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.